Flora Peyvandi / X
Jun 25, 2025, 15:23
Is the Glanzmann Era Finally Over? Flora Peyvandi on Latest Bispecific Antibodies: ISTH 2025
Flora Peyvandi, Professor of Internal Medicine at the University of Milan and former President of ISTH, shared a post on X:
”How to solve the problem of patients with Glanzmann using a novel bispecific abs – ISTH2025”
So, has the Glanzmann era truly ended—or is it just taking a coffee break before staging a comeback?
Sutacimig, a novel bispecific antibody with dual binding of FVIIa and TLT-1, seems to actually resolve the issues with clot formation in Glanzmann!
More of the latest ISTH2025 news to be posted on Hemostasis Today.
-
Mar 16, 2026, 16:14Siobhan Calafiore: Clinical Advantages of Apixaban Over Rivaroxaban in Reducing Bleeding Risk
-
Mar 16, 2026, 16:12Nuha El Sayed: Focused Summary of the 2026 ACC/AHA Guideline on Management of Dyslipidemia in Diabetes
-
Mar 16, 2026, 16:08Deepak Sudheendra: When a Vascular Looking Skin Pattern Isn’t Vascular
-
Mar 16, 2026, 16:06Surendra Karki։ Examining Blood Type and Coronary Heart Disease Risk in Australian Donors
-
Mar 16, 2026, 15:58Alan Nurden: Genome-Wide Analyses Unravel the Genetic Architecture of Coagulation and Fibrinolysis
-
Mar 16, 2026, 15:56Emmanuel J. Favaloro: Latest Publication from Sydney Centres on Heparin Therapy and Monitoring
-
Mar 16, 2026, 15:53Suvro Sankha Datta: Reporting Auto-Anti-Jk Antibodies in Children with Hematological Disorders
-
Mar 16, 2026, 15:44Francis Kynaston-Pearson: Why Randomised Controlled Trials Are the Gold Standard in Clinical Research
-
Mar 16, 2026, 15:18Kalpana Gupta Shekhawat: A Practical Clinical Approach to Iron Regulation